1 Min Read
Jan 30 (Reuters) - Vaxil Bio Ltd:
* VAXIL COMPLETES OVERSUBSCRIBED FINANCING TO ADVANCE ITS CANCER IMMUNOTHERAPY RESEARCH AND DEVELOPMENT Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.